Respiratory Inhaler Device Market Size

  • Report ID: 202
  • Published Date: Sep 04, 2024
  • Report Format: PDF, PPT

Respiratory Inhaler Device Market Size

Respiratory Inhaler Device Market size was valued at USD 37.07 billion in 2023 and is likely to reach USD 68.19 billion by 2036, expanding at around 4.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of respiratory inhaler device is estimated at USD 38.49 billion.

The growth of the market can be attributed to increasing cases of chronic obstructive pulmonary diseases. Furthermore, the data published by the World Health Organization states that asthma affected 262 million people in 2019 and caused 455,000 deaths worldwide. The inhaled medication can control asthma symptoms, which is the reason global market is projected to grow significantly during the forecast period. Additionally, the prevalence of chronic obstructive pulmonary diseases is directly related to tobacco smoking. The data released by the Institutes for Health Metrics and Evaluation states that the number of smokers is rising worldwide and in 2019, smoking caused 8 million deaths. On the back of an escalating number of people involved in smoking the market is estimated to grow significantly during the forecast period. The inhalers are effective in providing relief to common cold patients. On account of the efficacy in providing relief to common cold patients, the respiratory inhaler device market is projected to grow during the forecast period.


Respiratory Inhaler Device Market
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 202
  • Published Date: Sep 04, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of respiratory inhaler device is estimated at USD 38.49 billion.

Respiratory Inhaler Device Market size was valued at USD 37.07 billion in 2023 and is likely to reach USD 68.19 billion by 2036, expanding at around 4.8% CAGR during the forecast period i.e., between 2024-2036. The rising cases of chronic obstructive pulmonary diseases will impel the market growth.

North America is estimated to account for largest revenue share by 2036, on the back of presence of a highly established healthcare infrastructure.

The major players in the market are Merck & Co., Inc., GlaxoSmithKline plc., Cipla Inc., and Koninklijke Philips N.V.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample